Please assess the completion status of the following clinical trial:

Trial Title: ARFI Imaging for Targeted Prostate Biopsy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men who are scheduled to undergo ultrasound fusion-MR prostate biopsy;~* Men who are willing to participate in the study;~* Subjects must freely sign informed consent to enroll in the study;~* Assessing eligibility: eligibility for the study will be assessed, based upon the above criteria, by the participating urologist at the time of consultation.~* 18 years or older~Exclusion Criteria:~* Men who have had previous treatment for PCa including radiation, cryoablation, chemotherapy, surgery, high intensity focused ultrasound (HIFU), laser therapy or hormone therapy;~* Men who have had previous non-pharmacological invasive or minimally invasive treatment for benign prostatic hypertrophy (BPH) (i.e., TURP, TUMPT, WIT, TUNA, etc);~* standard pharmacological treatment of BPH is allowable~* Men who are mentally impaired and cannot give written consent;~* Men with anomalies of the rectum.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acoustic radiation force impulse (ARFI) (Type: EXPERIMENTAL): Patients with suspected PCa who are scheduled to undergo an ultrasound fusion-MR prostate biopsy.
- MR-ultrasound fusion (Type: ACTIVE_COMPARATOR): Patients with suspected PCa who are scheduled to undergo an ultrasound fusion-MR prostate biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).